Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420
Sherif S. Farag, Stephen L. George, Edward J. Lee, Maria Baer, Richard K. Dodge, Brian Becknell, Todd Fehniger, Lewis R. Silverman, Jeffrey Crawford, Clara D. Bloomfield, Richard A. Larson, Charles A. Schiffer, Michael A. Caligiuri
Research output: Contribution to journal › Article › peer-review
44Scopus
citations
Fingerprint
Dive into the research topics of 'Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420'. Together they form a unique fingerprint.